5

## What Is Claimed Is:

- 1. A method of screening for therapeutics for infectious diseases, comprising:
- (a) identifying host cell gene products selected from the group consisting of: host cell gene products which are upregulated during infection and host cell gene products which are expressed only during infection;
- (b) screening said host cell gene products for immunogenicity; and
- (c) determining which of said host cell gene products are immunogenic.
- 2. The method of claim 1, wherein said host cell gene products which are upregulated are expressed at a low level in uninfected cells of the same type.
- 3. The method of claim 1, wherein said host cell gene products which are upregulated are not expressed at all in uninfected cells of the same type.
- 4. The method of claim 1, wherein said infection is infection with human immunodeficiency virus (HIV).
- 5. The method of claim 1, wherein said screening for immunogenicity is screening for a cytotoxic T lymphocyte (CTL) response.
- 6. The method of claim 1, wherein said host cell gene products of (a) are identified using ordered microarrays of nucleic acids.
- 7. The method of claim 1, wherein said host cell gene products of (a) are identified using subtractive hybridization.

15

20

5

- 8. The method of claim 1, comprising:
- (a) identifying host cell gene products selected from the group consisting of: host cell gene products which are upregulated during infection and host cell gene products which are expressed only during infection;
- (b) identifying which of said host cell gene products of (a) are expressed during embryonic development;
- (c) screening the host cell gene products of (b) for immunogenicity; and
- (d) determining which of said host cell gene products of (b) are immunogenic.
  - 9. The method of claim 8, comprising:
- (a) identifying host cell gene products selected from the group consisting of: host cell gene products which are upregulated during infection and host cell gene products which are expressed only during infection;
- (b) identifying which of said host cell gene products of (a) are expressed during embryonic development;
- (c) identifying which of said host cell gene products of (b) are not expressed in adult tissues;
- (d) screening said host cell gene products of (c) for immunogenicity; and
- (e) determining which of said host cell gene products of (c) are immunogenic.
- 10. The method of claim 8, wherein said host cell gene products of (a) are identified using ordered microarrays of nucleic acids.
- 11. The method of claim 8, wherein said host cell gene products of (a) are identified using subtractive hybridization.

20

25

15

20

5

- 12. The method of claim 8, wherein said host cell gene products of (b) are identified using ordered microarrays of nucleic acids.
- 13. The method of claim 8, wherein said host cell gene products of (b) are identified using subtractive hybridization.
- 14. The method of claim 9, wherein said host cell gene products of (a) are identified using ordered microarrays of nucleic acids.
- 15. The method of claim 9, wherein said host cell gene products of (a) are identified using subtractive hybridization.
- 16. The method of claim 9, wherein said host cell gene products of (b) are identified using ordered microarrays of nucleic acids.
- 17. The method of claim 9, wherein said host cell gene products of (b) are identified using subtractive hybridization.
- 18. The method of claim 9, wherein said host cell gene products of (c) are identified using ordered microarrays of nucleic acids.
- 19. The method of claim 9, wherein said host cell gene products of (c) are identified using subtractive hybridization.
- 20. The method of claim 8, wherein said infection is infection with human immunodeficiency virus (HIV).
- 21. The method of claim 8, wherein said screening for immunogenicity is screening for a cytotoxic T lymphocyte (CTL) response.

- 22. The method of claim 9, wherein said infection is infection with human immunodeficiency virus (HIV).
- 23. The method of claim 9, wherein said screening for immunogenicity is screening for a cytotoxic T lymphocyte (CTL) response.